CALC Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
CalciMedica, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.44 |
| 52 Week High | US$8.38 |
| 52 Week Low | US$2.68 |
| Beta | 0 |
| 11 Month Change | -12.69% |
| 3 Month Change | -20.00% |
| 1 Year Change | -14.21% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -45.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| CALC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.3% | 4.2% | 2.0% |
| 1Y | -14.2% | 13.7% | 32.4% |
Return vs Industry: CALC underperformed the US Pharmaceuticals industry which returned 13.7% over the past year.
Return vs Market: CALC underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| CALC volatility | |
|---|---|
| CALC Average Weekly Movement | 13.7% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CALC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CALC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 13 | A. Leheny | www.calcimedica.com |
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company’s lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma.
CalciMedica, Inc. Fundamentals Summary
| CALC fundamental statistics | |
|---|---|
| Market cap | US$45.70m |
| Earnings (TTM) | -US$13.59m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.4x
P/E RatioIs CALC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CALC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.59m |
| Earnings | -US$13.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CALC perform over the long term?
See historical performance and comparison